5 completed, 1 terminated, 1 unknown, 1 withdrawn. 8 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Completed 5, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 2 | Terminated 1, Unknown 1 |
Follow oblimersen: new trials by email Literature Review of oblimersen trials Research Report on oblimersen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial of Dacarbazine With or Without Genasense in Advanced Melanoma dacarbazine plus Genasense, dacarbazine plus placebo - Melanoma | Phase 3 | Completed | Genta Incorporated | 300 | 2007-07-01 | 2011-11-07 |
| This Study is Being Performed to Evaluate the Effect of Genasense on the Efficacy and the Safety of Rituximab/Fludarabine Combination Treatment in Previously Untreated Subjects With Chronic Lymphocyctic Leukemia(CLL) Genasense® (, oblimersen sodium G3139) - Lymphocytic Leukemia | Phase 3 | Withdrawn | Genta Incorporated | 2006-06-01 | 2008-02-11 | |
| Pharmacokinetics of G3139 in Subjects With Advanced Melanoma, Including Those With Normal Hepatic Function and Those With Moderate Hepatic Impairment Genasense® (G3139, oblimersen sodium) - Advanced Melanoma and Normal or Impaired, Hepatic Function | Phase 2 / Phase 3 | Terminated | Genta Incorporated | 6 | 2005-08-01 | 2011-11-07 |
| Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia oblimersen sodium, cytarabine, daunorubicin hydrochloride - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Phase 3 | Completed | National Cancer Institute (NCI) | 500 | 2003-12-01 | 2026-06-01 |
| Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer oblimersen sodium, docetaxel - Lung Cancer | Phase 2 / Phase 3 | Unknown | Genta Incorporated | 2001-10-01 | 2014-01-06 | |
| Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia filgrastim, oblimersen sodium, cyclophosphamide - Leukemia | Phase 3 | Completed | Genta Incorporated | 2001-07-01 | 2014-01-06 | |
| Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma oblimersen sodium, dexamethasone - Multiple Myeloma and Plasma Cell Neoplasm | Phase 3 | Completed | Genta Incorporated | 2000-12-01 | 2014-01-06 | |
| Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma oblimersen sodium, dacarbazine - Melanoma (Skin) | Phase 3 | Completed | Genta Incorporated | 2000-07-01 | 2014-01-06 |
Melanoma (2) · Carcinoma, Non-Small-Cell Lung (1) · Congenital Abnormalities (1) · Leukemia (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Lymphoid (1) · Lung Neoplasms (1) · Multiple Myeloma (1) · Neoplasms, Plasma Cell (1) · Skin Neoplasms (1)
Genta Incorporated (7) · National Cancer Institute (NCI) (1)
United States (6) · Canada (2) · Australia (1) · Austria (1) · Czechia (1) · France (1) · Germany (1) · Italy (1) · Poland (1) · Russia (1) · Spain (1) · Switzerland (1) · United Kingdom (1)
Stanley R. Frankel, MD (3) · Deborah Braccia (1) · Guido Marcucci (1)
PMID 17296974, PMID 19373653, PMID 19738118, PMID 31171508, PMID 31375516, PMID 34251414, PMID 36184192
U10CA031946 (1)